Jhee S S, Gill M A, Yellin A E, Berne T V, Heseltine P N, Appleman M D
Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, USA.
Clin Ther. 1995 Jan-Feb;17(1):126-35. doi: 10.1016/0149-2918(95)80013-1.
Costs involved in using piperacillin 4 g/tazobactam 500 mg, given as intermittent intravenous infusions every 8 hours, were compared with those for imipenem/cilastatin 500 mg, given as intermittent intravenous infusions every 6 hours, for the treatment of patients with gangrenous or perforated appendicitis. A total of 88 patients were included in our cost analyses: 42 patients in the piperacillin/tazobactam group and 46 patients in the imipenem/cilastatin group. Durations (mean +/- SD) of antibiotic therapies were 7.8 +/- 3.3 days and 7.1 +/- 2.6 days for the piperacillin/tazobactam and imipenem/cilastatin groups, respectively. No statistical significance was found for the difference in duration of therapy (P = 0.376). Total drug treatment costs were $538.83 +/- $385.33 for the piperacillin/tazobactam group and $687.66 +/- $345.37 for the imipenem/cilastatin group. This difference in treatment cost was statistically significant (P = 0.0001). The need for laboratory tests and the use of other medications were not different between the two groups. Total hospital-days charges were higher for the piperacillin/tazobactam group ($18,339.76 +/- $6090.38) compared with the imipenem/cilastatin group ($16,150.00 +/- $5088.60) (P = 0.052). These findings suggest that length of hospital stay should be the economic focus of antibiotic therapy.
将哌拉西林4g/他唑巴坦500mg每8小时一次静脉滴注用于治疗坏疽性或穿孔性阑尾炎患者的费用，与亚胺培南/西司他丁500mg每6小时一次静脉滴注的费用进行了比较。共有88例患者纳入我们的成本分析：哌拉西林/他唑巴坦组42例患者，亚胺培南/西司他丁组46例患者。哌拉西林/他唑巴坦组和亚胺培南/西司他丁组抗生素治疗的持续时间（均值±标准差）分别为7.8±3.3天和7.1±2.6天。治疗持续时间的差异无统计学意义（P = 0.376）。哌拉西林/他唑巴坦组的总药物治疗费用为538.83美元±385.33美元，亚胺培南/西司他丁组为687.66美元±345.37美元。治疗费用的这种差异具有统计学意义（P = 0.0001）。两组间实验室检查需求和其他药物的使用情况无差异。哌拉西林/他唑巴坦组的总住院日费用（18,339.76美元±6090.38美元）高于亚胺培南/西司他丁组（16,150.00美元±5088.60美元）（P = 0.052）。这些发现表明住院时间应是抗生素治疗的经济关注点。
